Datopotamab Deruxtecan FDA Approval Path

Key Takeaways

• U.S.: accelerated approval June 23, 2025 for EGFR-mutated NSCLC after EGFR TKI and platinum chemotherapy.
• Pooled ORR 45%; median DOR 6.5 months (n=114 across TROPION-Lung05/Lung01).
• EU: NSCLC MAA voluntarily withdrawn; EMA noted provisional concerns on efficacy robustness and serious lung inflammation risk.
• Continued U.S. approval may depend on confirmatory benefit; EU lung access remains unresolved.

What did the datopotamab deruxtecan FDA approval cover?

FDA granted accelerated approval to Datroway (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic EGFR-mutated NSCLC who previously received EGFR-directed therapy and platinum-based chemotherapy. Recommended dosing is 6 mg/kg IV every three weeks (maximum 540 mg for patients ≥90 kg) until progression or unacceptable toxicity.

Primary agency notice: FDA accelerated approval announcement.

Why was the EU lung application withdrawn?

EMA’s public record states Daiichi Sankyo Europe withdrew the application for locally advanced or metastatic nonsquamous NSCLC. Based on data review at withdrawal, the Agency’s provisional opinion was that the medicine could not have been authorised for NSCLC. Concerns included uncertainty about whether the drug helps people live longer without their disease getting worse, protocol amendments that complicated subgroup interpretation, and serious side effects such as lung inflammation.

See the EMA withdrawal page for Datopotamab deruxtecan Daiichi Sankyo. AstraZeneca and Daiichi Sankyo said the withdrawal followed CHMP feedback and that they remain committed to lung-cancer development through additional pivotal trials.

How should analysts read the regional split?

U.S. accelerated approval creates near-term commercial optionality in a biomarker-defined NSCLC niche, but confirmatory trials must still verify clinical benefit. Europe’s lung path is delayed, so EU revenue models should not assume NSCLC labeling. Separately, Datroway/datopotamab deruxtecan has pursued breast-cancer indications in multiple regions; those labels must not be conflated with the withdrawn NSCLC MAA.

Trial evidence behind the U.S. lung label

Efficacy supporting accelerated approval came from a pooled subgroup of 114 EGFR-mutated patients treated at the recommended dose in TROPION-Lung05 (NCT04484142; single-arm) and TROPION-Lung01 (NCT04656652; randomized). Major endpoints were confirmed ORR and DOR by blinded independent central review per RECIST 1.1.

• ORR: 45% (95% CI 35–54)
• Median DOR: 6.5 months (95% CI 4.2–8.4)
• Program status: priority review and breakthrough therapy designation for the EGFR-mutated setting

What remains unproven

Accelerated approval is not the same as traditional approval with proven overall survival benefit. EU NSCLC authorization was not granted. Cross-trial comparisons to other Trop-2 ADCs or EGFR-pathway agents require caution. Safety monitoring for interstitial lung disease/pneumonitis remains central for ADC use in lung cancer.

Confirmatory obligations and ILD vigilance

Accelerated approval based on ORR and duration of response places clear pressure on confirmatory trials to show clinical benefit that sustains the U.S. lung indication. Until those data read out, payers and guidelines committees may treat Datroway’s EGFR-mutated NSCLC use as an option for heavily pretreated patients rather than a broad early-line standard. Interstitial lung disease and pneumonitis risk, flagged in EMA’s withdrawal discussion and typical for DXd ADCs, requires structured monitoring protocols in any real-world rollout.

Development programs spanning TROPION-Lung01, TROPION-Lung05, and additional pivotal lung studies remain the path to broaden or solidify labeling. Sponsors have publicly committed to continue lung-cancer development in Europe despite the withdrawn MAA, but timelines for a revised EU package are not fixed in the withdrawal summary.

Commercial modeling without conflating indications

Analysts should keep three buckets separate: U.S. accelerated NSCLC approval, EU NSCLC withdrawal, and any breast-cancer Datroway approvals in the U.S. or EU. Mixing those buckets produced the inaccurate “EMA backs lung cancer” framing. For BD and competitive intelligence, the correct 2026 read is a U.S.-led EGFR-mutated NSCLC foothold with Europe still unresolved for lung, while Trop-2 ADC competition continues across tumors.

Related NovaPharma coverage

• Vyloy zolbetuximab FDA approval
• Eli Lilly pipeline and deals outlook
• J&J TREMFYA UC Phase 3 data

Frequently Asked Questions

Primary Sources

1. FDA: Datroway accelerated approval for EGFR-mutated NSCLC
2. EMA: withdrawal of NSCLC marketing application
3. ClinicalTrials.gov NCT04656652 — TROPION-Lung01